{"organizations": [], "uuid": "03796a33153c77ee96242d2d4742bb6da140e3d0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-morphosys-galapagos-initiate-iguan/brief-morphosys-galapagos-initiate-iguana-phase-2-clinical-trial-with-mor106-in-atopic-dermatitis-patients-idUSFWN1S80KX", "country": "US", "domain_rank": 408, "title": "BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T23:27:00.000+03:00", "replies_count": 0, "uuid": "03796a33153c77ee96242d2d4742bb6da140e3d0"}, "author": "", "url": "https://www.reuters.com/article/brief-morphosys-galapagos-initiate-iguan/brief-morphosys-galapagos-initiate-iguana-phase-2-clinical-trial-with-mor106-in-atopic-dermatitis-patients-idUSFWN1S80KX", "ord_in_thread": 0, "title": "BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients", "locations": [], "entities": {"persons": [], "locations": [{"name": "galapagos", "sentiment": "none"}], "organizations": [{"name": "morphosys ag", "sentiment": "none"}, {"name": "morphosys", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 8:27 PM / Updated 11 minutes ago BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients Reuters Staff 1 Min Read\nMay 1 (Reuters) - Morphosys Ag:\n* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS\n* PLACEBO CONTROLLED, DOUBLE-BLIND STUDY WILL EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS (PK) OF MOR106 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T23:27:00.000+03:00", "crawled": "2018-05-01T23:42:17.023+03:00", "highlightTitle": ""}